FERRARO, SARA Statistiche
FERRARO, SARA
DIPARTIMENTO DI MEDICINA CLINICA E SPERIMENTALE
Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M
An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future
2021-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D.
Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study)
2021-01-01 Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M.
Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy
2021-01-01 Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M
Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study
2021-01-01 Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G
Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy
2021-01-01 Giometto, S; Convertino, I; Tuccori, M; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Turchetti, G; Trieste, L; Lorenzoni, V; Blandizzi, C; Mosca, M; Lucenteforte, E
Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs
2021-01-01 Ferraro, S.; Tuccori, M.; Convertino, I.; Valdiserra, G.; Cappello, E.; Maggi, F.; Blandizzi, C.; Focosi, D.
Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data
2021-01-01 Cucchiara, F.; Ferraro, S.; Luci, G.; Bocci, G.
Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy)
2021-01-01 Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Lucenteforte, E; Cappello, E; Valdiserra, G; Blandizzi, C; Gini, R; Tuccori, M
Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study
2021-01-01 Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E
Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases
2021-01-01 Convertino, I.; Cazzato, M.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Tillati, S.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M.
Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases
2021-01-01 Convertino, I; Cazzato, M; Giometto, S; Gini, R; Lucenteforte, E; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Lorenzoni, V; Trieste, L; Filippi, M; Turchetti, G; Cristofano, M; Blandizzi, C; Mosca, M; Tuccori, M
Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline
2020-01-01 Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D.
Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients
2020-01-01 Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C.
Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments
2020-01-01 Lombardi, N.; Bettiol, A.; Crescioli, G.; Ravaldi, C.; Bonaiuti, R.; Venegoni, M.; Vighi, G. D.; Mugelli, A.; Mannaioni, G.; Vannacci, A.; Aiezza, M. L.; Bettoni, D.; Blandizzi, C.; Borsi, V.; Capuano, A.; Cecchi, E.; Convertino, I.; Lungo, M. D.; Mauro, C. D.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Marra, A.; Marrazzo, E.; Monina, G.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rossi, M.; Rostan, S.; Ruocco, M.; Sironi, M.; Spada, G.; Sportiello, L.; Tuccori, M.; Vighi, G. V.
The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance
2020-01-01 Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C.
Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database
2020-01-01 Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M
Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy
2020-01-01 Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E
Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons
2020-01-01 Convertino, Irma; Lucenteforte, Ersilia; Gini, Rosa; Lorenzoni, Valentina; Cazzato, Massimiliano; Turchetti, Giuseppe; Trieste, Leopoldo; Ferraro, Sara; Leonardi, Luca; Roberto, Giuseppe; Luciano, Nicoletta; Blandizzi, Corrado; Mosca, Marta; Tuccori, Marco
Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease
2019-01-01 Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Adherence to mesalazine and identification of patients with ulcerative colitis in healthcare administrative databases of Tuscany (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Blandizzi, C; Lucenteforte, E; Gini, R; Tuccori, M | |
| An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future | 1-gen-2021 | Tuccori, M.; Convertino, I.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Fini, E.; Focosi, D. | |
| Analysis of fatal adverse drug events recorded in several Italian emergency departments (the MEREAFaPS study) | 1-gen-2021 | Pagani, S.; Lombardi, N.; Crescioli, G.; Vighi, G. V.; Spada, G.; Romoli, I.; Andreetta, P.; Capuano, A.; Marrazzo, E.; Marra, A.; Leoni, O.; Vannacci, A.; Venegoni, M.; Vighi, G. D.; Bettoni, D.; Blandizzi, C.; Bonaiuti, R.; Borsi, V.; Cecchi, E.; Convertino, I.; Del Lungo, M.; Di Mauro, C.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Monina, G.; Mugelli, A.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rostan, S.; Ruocco, M.; Sironi, M.; Sportiello, L.; Tuccori, M. | |
| Diagnostic delay, effectiveness and safety outcomes in a real-world cohort of patients with Crohn's disease: Data from administrative databases in Tuscany, Italy | 1-gen-2021 | Ferraro, S; Bartolini, C; Convertino, I; Bertani, L; Giometto, S; Cappello, E; Valdiserra, G; Tillati, S; Blandizzi, C; Lucenteforte, E; Costa, F; Gini, R; Tuccori, M | |
| Direct health care costs among patients with rheumatoid arthritis before and after the initiation of treatment with JAKi in Tuscany: The LEONARDO study | 1-gen-2021 | Lorenzoni, V; Tuccori, M; Gini, R; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E; Turchetti, G | |
| Longitudinal adherence trajectories to biologic disease modifying anti-rheumatic drugs in Tuscany, Italy | 1-gen-2021 | Giometto, S; Convertino, I; Tuccori, M; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Turchetti, G; Trieste, L; Lorenzoni, V; Blandizzi, C; Mosca, M; Lucenteforte, E | |
| Olfactory and gustatory impairments in COVID-19 patients: Role in early diagnosis and interferences by concomitant drugs | 1-gen-2021 | Ferraro, S.; Tuccori, M.; Convertino, I.; Valdiserra, G.; Cappello, E.; Maggi, F.; Blandizzi, C.; Focosi, D. | |
| Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data | 1-gen-2021 | Cucchiara, F.; Ferraro, S.; Luci, G.; Bocci, G. | |
| Trajectories of oral budesonide use in Crohn's disease cohort of Tuscan patients (Italy) | 1-gen-2021 | Bartolini, C; Ferraro, S; Convertino, I; Bertani, L; Giometto, S; Costa, F; Lucenteforte, E; Cappello, E; Valdiserra, G; Blandizzi, C; Gini, R; Tuccori, M | |
| Utilization patterns and healthcare accesses of JAKi used in rheumatoid arthritis patients in Tuscany: The LEONARDO study | 1-gen-2021 | Tuccori, M; Lorenzoni, V; Gini, R; Turchetti, G; Fini, E; Giometto, S; Bartolini, C; Paoletti, O; Convertino, I; Ferraro, S; Cappello, E; Valdiserra, G; Blandizzi, C; Lucenteforte, E | |
| Validation of algorithms for selecting rheumatoid arthritis patients in the Tuscan healthcare administrative databases | 1-gen-2021 | Convertino, I.; Cazzato, M.; Giometto, S.; Gini, R.; Valdiserra, G.; Cappello, E.; Ferraro, S.; Tillati, S.; Bartolini, C.; Paoletti, O.; Lorenzoni, V.; Trieste, L.; Filippi, M.; Turchetti, G.; Cristofano, M.; Blandizzi, C.; Mosca, M.; Lucenteforte, E.; Tuccori, M. | |
| Validation test for algorithms to identify rheumatoid arthritis patients in the Tuscan healthcare administrative databases | 1-gen-2021 | Convertino, I; Cazzato, M; Giometto, S; Gini, R; Lucenteforte, E; Valdiserra, G; Cappello, E; Ferraro, S; Tillati, S; Fornili, M; Bartolini, C; Paoletti, O; Lorenzoni, V; Trieste, L; Filippi, M; Turchetti, G; Cristofano, M; Blandizzi, C; Mosca, M; Tuccori, M | |
| Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline | 1-gen-2020 | Tuccori, M.; Ferraro, S.; Convertino, I.; Cappello, E.; Valdiserra, G.; Blandizzi, C.; Maggi, F.; Focosi, D. | |
| Exploring pharmacological approaches for managing cytokine storm associated with pneumonia and acute respiratory distress syndrome in COVID-19 patients | 1-gen-2020 | Convertino, I.; Tuccori, M.; Ferraro, S.; Valdiserra, G.; Cappello, E.; Focosi, D.; Blandizzi, C. | |
| Risk of hospitalisation associated with benzodiazepines and z-drugs in Italy: a nationwide multicentre study in emergency departments | 1-gen-2020 | Lombardi, N.; Bettiol, A.; Crescioli, G.; Ravaldi, C.; Bonaiuti, R.; Venegoni, M.; Vighi, G. D.; Mugelli, A.; Mannaioni, G.; Vannacci, A.; Aiezza, M. L.; Bettoni, D.; Blandizzi, C.; Borsi, V.; Capuano, A.; Cecchi, E.; Convertino, I.; Lungo, M. D.; Mauro, C. D.; Farina, G.; Ferraro, S.; Fucile, A.; Galfrascoli, E.; Geninatti, E.; Giovannetti, L.; Leonardi, L.; Liccardo, R.; Marra, A.; Marrazzo, E.; Monina, G.; Pagani, S.; Parrilli, M.; Rafaniello, C.; Rossi, F.; Rossi, M.; Rostan, S.; Ruocco, M.; Sironi, M.; Spada, G.; Sportiello, L.; Tuccori, M.; Vighi, G. V. | |
| The Impact of the COVID-19 “Infodemic” on Drug-Utilization Behaviors: Implications for Pharmacovigilance | 1-gen-2020 | Tuccori, M.; Convertino, I.; Ferraro, S.; Cappello, E.; Valdiserra, G.; Focosi, D.; Blandizzi, C. | |
| Time to biologic treatment and to total colectomy associated with diagnostic delay in ulcerative colitis: Analysis of an Italian regional administrative healthcare database | 1-gen-2020 | Ferraro, S; Bartolini, C; Bertani, L; Convertino, I; Lucenteforte, E; Costa, F; Valdiserra, G; Cappello, E; Blandizzi, C; Gini, R; Tuccori, M | |
| Trajectories of use of biologic disease modifying antirheumatic drugs in rheumatoid arthritis: A cohort study of Tuscan patients, Italy | 1-gen-2020 | Convertino, I; Giometto, S; Gini, R; Cazzato, M; Valdiserra, G; Cappello, E; Ferraro, S; Fornili, M; Turchetti, G; Lorenzoni, V; Trieste, L; Mosca, M; Blandizzi, C; Tuccori, M; Lucenteforte, E | |
| Utilisation patterns and clinical impact of the introduction of infliximab-biosimilar in Tuscany, Italy: real world evidence following the recommendation of switching for non-medical reasons | 1-gen-2020 | Convertino, Irma; Lucenteforte, Ersilia; Gini, Rosa; Lorenzoni, Valentina; Cazzato, Massimiliano; Turchetti, Giuseppe; Trieste, Leopoldo; Ferraro, Sara; Leonardi, Luca; Roberto, Giuseppe; Luciano, Nicoletta; Blandizzi, Corrado; Mosca, Marta; Tuccori, Marco | |
| Anti-tumor Necrosis Factor Drugs and Risk of Lymphoma in Patients with Inflammatory Bowel Disease | 1-gen-2019 | Blandizzi, C; Tuccori, M; Ferraro, S; Leonardi, L; Convertino, I |